Genfit SA/ FR0004163111 /
2024-05-20 5:35:11 PM | Chg. +0.295 | Volume | Bid3:01:10 AM | Ask3:01:10 AM | High | Low |
---|---|---|---|---|---|---|
3.770EUR | +8.49% | 503,987 Turnover: 1.86 mill. |
3.720Bid Size: 3,065 | 3.800Ask Size: 338 | 3.830 | 3.475 |
GlobeNewswire
04-25
GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
GlobeNewswire
04-15
GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
GlobeNewswire
04-05
GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report ...
GlobeNewswire
2023-12-08
GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangit...
GlobeNewswire
2023-12-07
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire
2023-12-07
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the trea...
GlobeNewswire
2023-12-06
GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a...
GlobeNewswire
2023-11-16
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
GlobeNewswire
2023-11-13
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaki...
GlobeNewswire
2023-11-13
GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as lat...
GlobeNewswire
2023-11-02
GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
GlobeNewswire
2023-09-26
GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Te...
GlobeNewswire
2023-09-20
GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
GlobeNewswire
2021-12-17
On heels of global strategic partnership announced today, GENFIT acquires rights to novel asset
GlobeNewswire
2021-12-17
GENFIT: Ipsen and GENFIT enter into exclusive licensing agreement for elafibranor, a Phase III asset...